179 related articles for article (PubMed ID: 31030414)
1. The Effects of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Volunteers: A Single-Sequence Crossover Study.
Garonzik S; Byon W; Myers E; Li X; Marchisin D; Murthy B
Am J Cardiovasc Drugs; 2019 Dec; 19(6):561-567. PubMed ID: 31030414
[TBL] [Abstract][Full Text] [Related]
2. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.
Frost CE; Byon W; Song Y; Wang J; Schuster AE; Boyd RA; Zhang D; Yu Z; Dias C; Shenker A; LaCreta F
Br J Clin Pharmacol; 2015 May; 79(5):838-46. PubMed ID: 25377242
[TBL] [Abstract][Full Text] [Related]
3. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects.
Frost C; Wang J; Nepal S; Schuster A; Barrett YC; Mosqueda-Garcia R; Reeves RA; LaCreta F
Br J Clin Pharmacol; 2013 Feb; 75(2):476-87. PubMed ID: 22759198
[TBL] [Abstract][Full Text] [Related]
4. Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study.
Kreutz R; Persson PB; Kubitza D; Thelen K; Heitmeier S; Schwers S; Becka M; Hemmrich M
J Thromb Haemost; 2017 Oct; 15(10):2017-2028. PubMed ID: 28805299
[TBL] [Abstract][Full Text] [Related]
5. Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters.
Gidal BE; Maganti R; Laurenza A; Yang H; Verbel DA; Schuck E; Ferry J
Epilepsy Res; 2017 Aug; 134():41-48. PubMed ID: 28535410
[TBL] [Abstract][Full Text] [Related]
6. Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa.
Vakkalagadda B; Frost C; Byon W; Boyd RA; Wang J; Zhang D; Yu Z; Dias C; Shenker A; LaCreta F
Am J Cardiovasc Drugs; 2016 Apr; 16(2):119-27. PubMed ID: 26749408
[TBL] [Abstract][Full Text] [Related]
7. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects.
Upreti VV; Wang J; Barrett YC; Byon W; Boyd RA; Pursley J; LaCreta FP; Frost CE
Br J Clin Pharmacol; 2013 Dec; 76(6):908-16. PubMed ID: 23488672
[TBL] [Abstract][Full Text] [Related]
8. Relative Bioavailability of Apixaban Solution or Crushed Tablet Formulations Administered by Mouth or Nasogastric Tube in Healthy Subjects.
Song Y; Wang X; Perlstein I; Wang J; Badawy S; Frost C; LaCreta F
Clin Ther; 2015 Aug; 37(8):1703-12. PubMed ID: 26188837
[TBL] [Abstract][Full Text] [Related]
9. Randomized, blinded, placebo- and positive-controlled crossover study to determine the effect of multiple doses of apixaban on the QTc interval.
Frost C; Nepal S; Byon W; Moore K; Reeves RA; Boyd R; LaCreta F
J Clin Pharmacol; 2015 May; 55(5):549-55. PubMed ID: 25501868
[TBL] [Abstract][Full Text] [Related]
10. Effect of Multiple Oral Doses of the Potent CYP3A4 Inhibitor Clarithromycin on the Pharmacokinetics of a Single Oral Dose of Vonoprazan: A Phase I, Open-Label, Sequential Design Study.
Jenkins H; Jenkins R; Patat A
Clin Drug Investig; 2017 Mar; 37(3):311-316. PubMed ID: 27928738
[TBL] [Abstract][Full Text] [Related]
11. Regional Gastrointestinal Absorption of Apixaban in Healthy Subjects.
Byon W; Nepal S; Schuster AE; Shenker A; Frost CE
J Clin Pharmacol; 2018 Jul; 58(7):965-971. PubMed ID: 29578609
[TBL] [Abstract][Full Text] [Related]
12. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects.
Yamahira N; Frost C; Fukase H; Yu Z; Wang J; Pursley J; LaCreta F; Hiraoka M
Int J Clin Pharmacol Ther; 2014 Jul; 52(7):564-73. PubMed ID: 24725442
[TBL] [Abstract][Full Text] [Related]
13. Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs.
Mikus G; Foerster KI; Schaumaeker M; Lehmann ML; Burhenne J; Haefeli WE
Clin Pharmacokinet; 2019 Sep; 58(9):1155-1163. PubMed ID: 30828771
[TBL] [Abstract][Full Text] [Related]
14. Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban.
Frost CE; Song Y; Shenker A; Wang J; Barrett YC; Schuster A; Harris SI; LaCreta F
Clin Pharmacokinet; 2015 Jun; 54(6):651-62. PubMed ID: 25573421
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban.
Frost C; Shenker A; Gandhi MD; Pursley J; Barrett YC; Wang J; Zhang D; Byon W; Boyd RA; LaCreta F
Br J Clin Pharmacol; 2014 Oct; 78(4):877-85. PubMed ID: 24697979
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis.
Wang X; Tirucherai G; Marbury TC; Wang J; Chang M; Zhang D; Song Y; Pursley J; Boyd RA; Frost C
J Clin Pharmacol; 2016 May; 56(5):628-36. PubMed ID: 26331581
[TBL] [Abstract][Full Text] [Related]
17. Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study.
Song Y; Wang Z; Perlstein I; Wang J; LaCreta F; Frost RJA; Frost C
J Thromb Haemost; 2017 Nov; 15(11):2125-2137. PubMed ID: 28846831
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Crushed Tablet for Oral Administration and the Effect of Food on Apixaban Pharmacokinetics in Healthy Adults.
Song Y; Chang M; Suzuki A; Frost RJ; Kelly A; LaCreta F; Frost C
Clin Ther; 2016 Jul; 38(7):1674-1685.e1. PubMed ID: 27292282
[TBL] [Abstract][Full Text] [Related]
19. Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects.
Wang X; Mondal S; Wang J; Tirucherai G; Zhang D; Boyd RA; Frost C
Am J Cardiovasc Drugs; 2014 Apr; 14(2):147-54. PubMed ID: 24277644
[TBL] [Abstract][Full Text] [Related]
20. An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants.
Li J; Rockich K; Yuska B; Zhou G; Epstein N; Punwani N; Chen X; Yeleswaram S
J Clin Pharmacol; 2020 Nov; 60(11):1519-1526. PubMed ID: 32515832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
